Romiplostim N01
Sponsors
Shandong University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Institute of Hematology & Blood Diseases Hospital, China
Conditions
Acute Myeloid LeukemiaAdolescentBreast CancerCTIT-Chemotherapy Induced ThrombocytopeniaCTIT: Cancer Therapy Induced ThrombocytopeniaCancer Treatment-induced Thrombocytopenia (CTIT)Chemotherapy Induced ThrombocytopeniaChemotherapy-induced Thrombocytopenia
Phase 1
Phase 2
Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT
RecruitingNCT06693791
Start: 2024-12-01End: 2026-12-01Target: 34Updated: 2024-11-18
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
Not yet recruitingNCT06898983
Start: 2025-03-31End: 2027-02-28Target: 97Updated: 2025-03-28
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Not yet recruitingNCT07043894
Start: 2025-07-01End: 2026-09-01Target: 50Updated: 2025-06-29
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
RecruitingNCT07063225
Start: 2025-08-31End: 2026-08-31Target: 50Updated: 2025-07-14
Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors
Not yet recruitingNCT07128576
Start: 2025-09-15End: 2028-12-31Target: 60Updated: 2025-09-04
Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
Not yet recruitingNCT07400250
Start: 2026-04-01End: 2028-10-01Target: 28Updated: 2026-02-10
Phase 3
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
Not yet recruitingNCT06440824
Start: 2024-06-01End: 2025-11-30Target: 60Updated: 2024-06-04
FRIENDS-01:A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
Not yet recruitingNCT06759636
Start: 2025-01-21End: 2026-07-21Target: 88Updated: 2025-01-06
A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia
Not yet recruitingNCT07345000
Start: 2026-01-31End: 2030-08-31Target: 210Updated: 2026-01-15
Unknown Phase
Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients
Not yet recruitingNCT07162519
Start: 2025-09-20End: 2026-11-30Target: 68Updated: 2025-09-09
A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
Not yet recruitingNCT07185893
Start: 2025-09-30End: 2028-12-31Target: 106Updated: 2025-09-22
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
RecruitingNCT07206823
Start: 2025-09-01End: 2027-07-31Target: 30Updated: 2025-12-04